Retatrutide Phase 2/3 Review: What Lilly's Data Shows So Far

A Lilly-source review of retatrutide Phase 2 and Phase 3 data, including TRIUMPH-1, TRIUMPH-4, TRANSCEND-T2D-1, and what the results mean for metabolic research.

Retatrutide has moved from an unusually strong Phase 2 obesity signal into a broad Phase 3 program spanning obesity, type 2 diabetes, osteoarthritis-associated obesity, obstructive sleep apnea substudies, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Based on Eli Lilly disclosures through 2026, the molecule is no longer simply an early-stage triple agonist concept; it is now a late-stage test of whether simultaneous GIP, GLP-1, and glucagon receptor activation can deliver larger and more durable metabolic effects than earlier incretin classes.

Mechanistic frame: why triple agonism matters

Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. For researchers, the important point is that retatrutide is not just another GLP-1 analog. The molecule is designed to combine appetite and glycemic biology with a glucagon-receptor axis linked to energy expenditure and hepatic lipid handling.

Phase 2: the signal that justified TRIUMPH

In Lilly's June 2023 Phase 2 announcement, retatrutide met the primary endpoint in adults with obesity or overweight without diabetes. Lilly reported mean body weight reduction up to 17.5% at 24 weeks and up to 24.2% at 48 weeks as a secondary endpoint. The company also reported exploratory improvements in cardiometabolic measures including blood pressure, triglycerides, LDL cholesterol, total cholesterol, HbA1c, fasting glucose, and fasting insulin.

The Phase 2 safety language was also important: Lilly said gastrointestinal adverse events were the most common, generally mild to moderate, and usually occurred during dose escalation. That is broadly consistent with incretin-class tolerability patterns, but it did not remove the need for longer and larger Phase 3 safety datasets.

Phase 3 snapshot: what Lilly has reported so far

TRIUMPH-1: the pivotal obesity readout

Lilly's May 2026 TRIUMPH-1 announcement is the most important obesity update so far. In adults without diabetes, all studied doses met the primary and key secondary obesity endpoints at 80 weeks. Lilly reported average body weight reductions of 19.0% at 4 mg, 25.9% at 9 mg, and 28.3% at 12 mg, compared with 2.2% for placebo. The 12 mg arm also had 45.3% of participants achieving at least 30% body weight reduction.

Two details matter for interpretation. First, the 4 mg dose reached with a simpler escalation schedule still produced nearly 20% average weight loss, which may matter for tolerability and protocol design. Second, Lilly reported that participants with baseline BMI of at least 35 who continued in a blinded extension reached up to 30.3% average weight loss at 104 weeks, suggesting that duration remains central to interpreting the full effect size.

TRIUMPH-4 and comorbidity endpoints

TRIUMPH-4 tested retatrutide in adults with obesity or overweight and knee osteoarthritis. Lilly reported that the two highest investigated doses met co-primary endpoints for body weight and WOMAC pain-score reduction at 68 weeks. The 12 mg arm reached 28.7% average weight reduction, and Lilly reported substantial pain and physical-function changes versus placebo.

For laboratory readers, this is not just an 'obesity trial with a pain measure.' It points to a broader research question: when weight, inflammation, mechanical load, and mobility interact, should incretin-based and multi-receptor metabolic studies measure downstream functional endpoints as well as body composition?

TRANSCEND-T2D-1: glycemic and weight endpoints together

In March 2026, Lilly reported the first Phase 3 type 2 diabetes readout for retatrutide. In TRANSCEND-T2D-1, the company said retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks, and the 12 mg group lost an average of 36.6 lb, or 16.8%. Lilly also stated that no weight-loss plateau was observed through 40 weeks.

This matters because weight loss in type 2 diabetes populations is often smaller than in non-diabetic obesity populations. The T2D signal gives researchers a separate metabolic context for evaluating triple agonism, insulin sensitivity, glycemic control, and body-weight trajectories.

What is still unresolved

• Several 2025 and 2026 updates are topline company disclosures rather than full peer-reviewed publications.
• Longer-term tolerability, discontinuation patterns, and rare adverse events require large datasets and regulatory review.
• The relative contribution of GIP, GLP-1, and glucagon receptor activation cannot be inferred from body-weight outcomes alone.
• Trial populations, escalation schedules, and endpoint definitions differ across TRIUMPH and TRANSCEND studies.
• Retatrutide remains investigational; Lilly disclosures do not make research-grade material suitable for human or veterinary use.

Research analysis: what the Phase 2 to Phase 3 transition tells us

The retatrutide story is now less about whether the molecule can produce a large short-term body-weight signal and more about where the ceiling, durability, and tolerability limits sit across populations. Phase 2 showed a striking signal at 48 weeks. TRIUMPH-1 and TRIUMPH-4 extend that signal into longer and more clinically complex Phase 3 settings. TRANSCEND-T2D-1 adds a glycemic-control dimension. Together, the data support retatrutide as a major research reference point for multi-receptor metabolic pharmacology.

The key caveat is that company-reported topline results should be treated as a roadmap, not the final manuscript. Researchers should wait for complete datasets, peer-reviewed publications, and regulatory review before treating the program's effect sizes, safety profile, or subgroup findings as settled.

Sources reviewed

• Eli Lilly investor release, June 26, 2023: Phase 2 retatrutide results published in The New England Journal of Medicine.
• Eli Lilly investor release, December 11, 2025: TRIUMPH-4 knee osteoarthritis and obesity Phase 3 topline results.
• Eli Lilly investor release, March 19, 2026: TRANSCEND-T2D-1 Phase 3 type 2 diabetes topline results.
• Eli Lilly investor release, May 21, 2026: TRIUMPH-1 pivotal Phase 3 obesity topline results.
• Lilly Medical, retatrutide obesity clinical trials overview: TRIUMPH Phase 3 program structure and endpoints.

Retatrutide is investigational. PeptidesLab content is commercial educational material for laboratory research audiences only and is not medical advice, dosing guidance, or a recommendation for human or veterinary use.

Research use only. Educational commercial content.